DeepMed Research

Dabigatran

Generic Name: Dabigatran

Brand Names: Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₅N_₇O_₃

CAS Number: 211914-51-1

Unique Ingredient Identifier: I0VM4M70GC

Background: Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

Clinical Trials

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

Active, not recruiting

Conditions: Atrial Fibrillation

Interventions: Drug: Apixaban
Drug: Edoxaban
Drug: Rivaroxaban
Drug: Dabigatran

First Posted Date: 2020-03-05

Last Posted Date: 2023-06-06

Lead Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Target Recruit Count: 700

Registration Number: NCT04297150

Locations: 🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain
🇪🇸
Hospital Gómez Ulla, Madrid, Spain
🇪🇸
Hospital Universitario de La Paz, Madrid, Spain

and more 3 locations

A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosuvastatin + BI 1323495
Drug: Rosuvastatin
Drug: Dabigatran etexilate
Drug: Dabigatran etexilate + BI 1323495

First Posted Date: 2020-02-05

Last Posted Date: 2024-02-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT04257032

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto)
Drug: Warfarin
Drug: Apixaban
Drug: Dabigatran

First Posted Date: 2020-01-31

Last Posted Date: 2024-08-01

Lead Sponsor: Bayer

Target Recruit Count: 134897

Registration Number: NCT04249401

Locations: 🇸🇪
Many locations, Multiple Locations, Sweden

Registration of Idarucizumab for Patients with IntraCranial Hemorrhage

Completed

Conditions: Intracranial Hemorrhage

Interventions: Drug: Dabigatran Etexilate Oral Capsule [Pradaxa]
Drug: Vitamin K antagonist
Drug: Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]

First Posted Date: 2019-08-20

Last Posted Date: 2024-12-09

Lead Sponsor: University Hospital, Essen

Target Recruit Count: 104

Registration Number: NCT04062097

Locations: 🇩🇪
Klinikum Schön Klinik Bad Aibling SE & Co. KG, Bad Aibling, Germany
🇩🇪
Hochtaunuskliniken GmbH, Bad Homburg, Germany
🇩🇪
Rhön Klinikum Campus Bad Neustadt, Bad Neustadt An Der Saale, Germany

and more 30 locations

DOAC Versus VKA After Cardiac Surgery

Phase 2

Withdrawn

Conditions: Anticoagulant-induced Bleeding

Interventions: Drug: Warfarin
Drug: Dabigatran
Drug: Rivaroxaban
Drug: Apixaban
Drug: Edoxaban

First Posted Date: 2019-06-28

Last Posted Date: 2023-03-13

Lead Sponsor: Laval University

Registration Number: NCT04002011

PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

Phase 3

Completed

Conditions: Atrial Fibrillation
Intracerebral Hemorrhage

Interventions: Drug: Apixaban Oral Tablet
Drug: Dabigatran
Drug: Edoxaban Tablets
Drug: Rivaroxaban

First Posted Date: 2019-06-25

Last Posted Date: 2025-01-13

Lead Sponsor: Imperial College London

Target Recruit Count: 319

Registration Number: NCT03996772

Locations: 🇦🇹
Krankenhaus der Barmherzigen Brüder Eisenstadt, Eisenstadt, Austria
🇦🇹
Universitätsklinikum St. Pölten, St. Pölten, Austria
🇩🇪
Klinikum Altenburger Land, Altenburg, Germany

and more 61 locations

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

Phase 3

Recruiting

Conditions: Stroke, Ischemic

Interventions: Drug: Aspirin
Drug: Dabigatran
Drug: Apixaban
Drug: Clopidogrel
Drug: Edoxaban

First Posted Date: 2019-05-23

Last Posted Date: 2023-08-16

Lead Sponsor: University of Zurich

Target Recruit Count: 620

Registration Number: NCT03961334

Locations: 🇬🇷
Attikon University Hospital, Athens, Greece
🇪🇸
Hospital Universitario Virgen Macarena, Sevilla, Spain
🇨🇭
University Hospital of Basel, Basel, Switzerland

and more 11 locations

Treating Acute Pancreatitis With Dabigatran, a Pilot Study

Phase 1

Terminated

Conditions: Acute Pancreatitis

Interventions: Drug: Dabigatran Etexilate Mesylate
Other: Standard of Care

First Posted Date: 2019-01-17

Last Posted Date: 2022-09-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 2

Registration Number: NCT03807856

Locations: 🇺🇸
Mayo clinic, Jacksonville, Florida, United States

A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.

Phase 1

Withdrawn

Conditions: Mild Cognitive Impairment
Mild Alzheimer's Disease

Interventions: Drug: Placebo - Cap
Drug: Dabigatran

First Posted Date: 2018-11-23

Last Posted Date: 2025-04-17

Lead Sponsor: University of Rhode Island

Target Recruit Count: 40

Registration Number: NCT03752294

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04965842
Drug: Dabigatran

First Posted Date: 2018-11-15

Last Posted Date: 2020-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT03742336

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy